Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about DURECT CORPORATION
10/26DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Busines..
PR
10/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Confere..
PR
09/23DURECT CORPORATION : Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2..
PR
09/15DURECT CORPORATION : Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTec..
PR
09/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright Annual Global Investment Confere..
PR
08/02DURECT : Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target
MT
08/02DURECT : Files for Up to $250 Million Mixed-Securities Shelf
MT
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q2 Revenue $2.3M, vs. Street Est..
MT
07/29DURECT CORPORATION : Announces Second Quarter 2021 Financial Results and Update of Program..
PR
07/29Durect Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/22DURECT CORPORATION : to Announce Second Quarter 2021 Financial Results and Provide Busines..
PR
07/14DURECT CORPORATION : to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
PR
06/23DURECT : Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1..
PU
06/23DURECT CORPORATION : Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH..
PR
06/23DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NAS..
CI
06/16DURECT : Certificate of Amendment to the Amended and Restated Certificate of Incorporation..
PU
06/09DURECT CORPORATION : to Present Additional Clinical Data from DUR-928 Studies in NASH (Pha..
PR
06/09DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and..
CI
06/02DURECT : FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Form 8-K)
PU
06/02DURECT Corporation and Oxford Finance LLC Enters into Fifth Amendment Loan and Security..
CI
05/04DURECT : Q1 Earnings Snapshot
AQ
05/04DURECT CORPORATION ANNOUNCES FIRST Q : 30 p.m. ET
PU
05/04DURECT CORPORATION : Announces First Quarter 2021 Financial Results and Update of Programs
PR
05/04Durect Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
04/27DURECT CORPORATION : to Announce First Quarter 2021 Financial Results and Provide Business..
PR
04/23Armand P. Neukermans, Class III Director of Durect Corporation, Not to Stand for Re-Ele..
CI
04/05Certain Stock Options of DURECT Corporation are subject to a Lock-Up Agreement Ending o..
CI
04/05Certain Common Stock of DURECT Corporation are subject to a Lock-Up Agreement Ending on..
CI
03/21DURECT CORPORATION(NASDAQCM : DRRX) added to S&P Pharmaceuticals Select Industry Index
CI
03/09DURECT CORPORATION : Announces Publication of DUR-928's Mechanism of Action
PR
03/09Durect Corporation Announces Publication of Dur-928'S Mechanism of Action
CI
03/04DURECT : Swings to Profit in Q4
MT
03/04DURECT : Q4 Earnings Snapshot
AQ
03/04DURECT : Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 EPS $0.02, vs. Street Est of $-..
MT
03/04DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q4 Revenue $2.2M, vs. Street Est..
MT
03/04Durect Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2..
CI
03/04DURECT CORPORATION : Announces Fourth Quarter and Full Year 2020 Financial Results and Upd..
PR
03/03DURECT CORPORATION : to Participate in Three Investor Conferences in March 2021
PR
02/25DURECT CORPORATION : to Announce 2020 Financial Results and Provide Business Update on Mar..
PR
02/04DURECT CORPORATION : Announces Pricing of $42.5 Million Public Offering of Common Stock
PR
02/03DURECT CORPORATION : Announces Proposed Offering of Common Stock
PR
02/03DURECT : Chardan Adjusts Price Target on Durect to $8 From $7, Maintains Buy Rating
MT
02/03DURECT CORPORATION : Announces U.S. FDA Approval of POSIMIR for Post-Surgical Pain Reducti..
AQ
02/02DURECT : Secures FDA Approval for Posimir Analgesic; Shares Jump
MT
02/02DURECT CORPORATION : Announces U.S. FDA Approval of POSIMIR« For Post-Surgical Pain Reduct..
PR
02/02DURECT Corporation Announces U.S. FDA Approval of POSIMIR« for Post-Surgical Pain Reduc..
CI
01/25DURECT : Doses First Patient in Phase 2 Study of DUR-928 to Treat Severe Alcohol-Associate..
MT
01/25DURECT CORPORATION : Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in ..
PR
01/25DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in..
CI
01/05DURECT Corporation Announces Board Changes
CI
01/05DURECT CORPORATION : Appoints Two New Board Members
PR
01/04DURECT CORPORATION : Announces Closing of LACTEL« Absorbable Polymer Product Line Sale to ..
PR
01/04DURECT Corporation Announces Closing of LACTEL« Absorbable Polymer Product Line Sale to..
CI
2020Evonik Industries AG completed the acquisition of LACTEL Absorbable Polymer Product Lin..
CI
2020DURECT CORPORATION : to Participate in Investor Conferences in January 2021
PR
2020DURECT : Says FDA Grants Fast-Track Designation to Alcoholic Hepatitis Drug
MT
2020DURECT CORPORATION : Announces DUR-928 Granted FDA Fast Track Designation for Treatment of..
PR
2020DURECT Corporation Announces Dur-928 Granted Fda Fast Track Designation for Treatment o..
CI
2020DURECT CORPORATION : to Sell its LACTEL Absorbable Polymer Product Line to Evonik for $15 ..
AQ
2020DURECT : To Sell Lactel Product Line To Evonik For $15 Million
MT
2020DURECT CORPORATION : to Sell its LACTEL« Absorbable Polymer Product Line to Evonik for $15..
PR
2020Evonik Industries AG signed an agreement to acquire LACTEL Absorbable Polymer Product L..
CI
2020DURECT CORPORATION : Announces Additional Safety Data and Efficacy Signals from Phase 1b C..
AQ
2020DURECT : Additional Data Show Promising DUR-928 Profile in Liver Disease; Stock Up 6%
MT
2020DURECT CORPORATION : Announces Additional Safety Data and Efficacy Signals from Phase 1b C..
PR
2020DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b ..
CI
2020DURECT CORPORATION : to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chi..
AQ
2020DURECT Corporation Appoints Norman Sussman as Chief Medical Officer
CI
2020DURECT CORPORATION : Appoints Dr. Norman Sussman as Chief Medical Officer
AQ
2020DURECT CORPORATION : Announces Third Quarter 2020 Financial Results and Update of Programs
AQ
2020DURECT : 3Q Earnings Snapshot
AQ
2020DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q3 Revenue $2.7M, vs. Street Est..
MT
2020DURECT CORPORATION : Announces Third Quarter 2020 Financial Results and Update of Programs
PR
1  2  3  4  5  6Next
Upcoming event on DURECT CORPORATION
11/08/21